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ADVANCED CARE PLANNING (ACP) BEFORE STEM CELL TRANSPLANTA-
TION (SCT) TREATMENT BEGINS
Neumann, J.L., Gallagher, C., Epner, D., Susan, G., Buitrago, J.,
Richard, C. The University of Texas MD Anderson Cancer Center, Hous-
ton, TX
SCT is a high risk/reward proposition. Many experienced SCT
practitioners perceive that SCT patients are not consistently pre-
pared for the possibility of life threatening complications and
poor outcomes. The SCT department was selected to pilot
a patient-centered intervention to improve ACP discussions in
our institution. ACP is an extraordinarily complex process, and
many patient, provider, and system factors influence whether dis-
cussions occur.
Aim: Increase SCT patients’ awareness of the possibility of life
threatening complications and poor outcomes by examining the
number of advance directives (AD) and/or documentation of ACP
conversations by at least 10%.
Interventions: A patient-centered educational initiative was devel-
oped. An existing admission class was enhanced by distributing a pre-
viously created ACP document. Salient points were discussed and
patients were encouraged to talk to their providers prior to admission
if they had any additional questions or concerns.
Results: A chart audit for documentation of ACP discussions and
AD documents before (N 5 32) and after (N 5 35) the intervention
was used. A patient survey was used to assess the patients’ response to
ACP information presented in the class. Twelve (37%) AD docu-
ments were found before the intervention and 14 (40%) after. Doc-
umentation of the conversations between patients and providers
(MD, PA, SW) occurred with 23 (72%) patients before the interven-
tion and 31 (89%) after the intervention. Patient evaluations indi-
cated the majority agreed or strongly agreed that this information
was understandable, useful and prompted them to think about deci-
sions and discussions theymay need to have with family and care pro-
viders.
Conclusions: Because of the brief duration, we were unable to
identify cost savings. However, based on improved understanding
of ACP and patient-provider shared determinations of best pa-
tient-centered practice, further investigation is warranted which
will include review of length of stay and changes in ICU usage
and related cost savings. We have continued the intervention and
are collecting additional data. Interventions will be modified as in-
dicated, and we will continue to work on developing other metrics.
Further, we plan to examine more specifically the meaning of a sub-
stantive conversation, leading to the development of trigger points
for discussions. We ultimately expect to develop guidelines and
training for providers, and continue to promote the importance
of ACP.574
INTEGRATING HSCT EVALUATION-PHASE ACTIVITIES TO REDUCE COST
AND STREAMLINE WORKFLOW
Kostaras, P.M., Emmert, A.E. Dana-Farber/Brigham &Women’s Can-
cer Center, Boston, MA
The evaluation process required for insurance approval for
HSCT occurs alongside the clinical work-up process which is
in part governed by eligibility assessment standards set by
FACT, the FDA, and other regulatory bodies. In a large academic
cancer center, the functional differentiation among clinical staff,
financial registrars and counselors, and transplant coordinators
supporting patient case management during the evaluation phase
for HSCT tends to generate separate standard work flows for
each function, leading to inefficiency among staff and overuse
of clinical testing. A workflow and decision tree analysis demon-
strated an opportunity to create a single process engaging all co-
ordination and clinical evaluation functions to reduce time to
insurance approval, reduce overall effort for staff, reduce excess
testing, and produce greater clarity and comfort for patients.
Benefit review and documentation, testing requirements, hand-
offs for appropriate peer to peer discussion and negotiation
were all addressed as distinct processes that required optimizedand integrated process improvement. The new workflow involves
time point requirements and decision trees to ensure consistency
and compliance. A focus on reducing non-critical or repeat test-
ing generated a greater use of existing testing results and the ed-
ucation of payer case managers in FACT and cancer center
eligibility standards effectively reduced requirements for early
or up front testing that would need to be repeated prior to admis-
sion. Implementation revealed further opportunities for stream-
lining which were incorporated into the process. Outcomes
show marked reduction/elimination of non-clinically valuable or
duplicate testing, faster insurance authorization, and greater
throughput relative to staffing levels.575
EFFORTS TO MANAGE AND REDUCE DISCHARGE PHARMACY CRISES
AMONG HIGH RISK HSCT PATIENTS
Gaumer, C., Holland, D., Emmert, A. Dana-Farber/Brigham & Wom-
en’s Cancer Center, Boston, MA
The HSCT program at Dana-Farber/Brigham and Women’s
Cancer Center was experiencing increasing instances of unex-
pected pharmacy benefit crises and associated delayed dis-
charge, provision of emergency medications at time of
discharge at the expense of the hospital, and last minute crisis
management by many staff members. After review and analysis
of the root causes for these problems, an infrastructure was es-
tablished to focus on early intervention during the HSCT work-
up process to identify and address a set of risks associated with
a significant subset of HSCT patients, including psychosocial
support needs, lack of outpatient caregiver, financial shortfalls,
complex pharmacy benefit plans and insurance restrictions
that contribute to medication access crises. New positions
were proposed and filled – an Ambulatory Care Coordination
Nurse (ACCRN) and a Pharmacy Resource Specialist (PRS).
These key resources work together with other members of pa-
tients’ transplant team from social work, ambulatory and inpa-
tient care coordination, the clinical team, the transplant
coordination team, and financial counseling staff. The ACCRN
researches the patient’s high risk issues, incorporating patient
information provided by other team members to plan a safe
and organized discharge. Pharmacy benefits and calculation of
the expected pharmacy costs are presented to the patient in
advance of the transplant admission. The PRS researches drug
assistance programs as needed. The CCRN and the PRS discuss
drug coverage options with the patient and assist with comple-
tion of necessary paperwork. After 18 months of service, this
effort has yielded significantly fewer discharge medication is-
sues, has reduced emergency medication dispensing at the
time of discharge, generated a smoother discharge path for
the inpatient care coordination and clinical team, generated
greater patient satisfaction and understanding of post transplant
care and costs, and reduced instances of extended days in hos-
pital due to delayed discharge.576
ASSESSMENT AND REVISION OF PATIENT SCHEDULING FOR HSCT
RELATED APHERESIS AND CELL PROCESSING TO REDUCE OVER-
ALLOCATION AND UNDERUTILIZATION OF RESOURCES
King, B.S., Ellis, M., Schott, D.M., Kostaras, P.M., Emmert, A.E.
Dana-Farber/Brigham & Women’s Cancer Center, Boston, MA
With the initiation of the use of plerixafor and its impact on
apheresis flow and utilization relative to HSCT in a large aca-
demic cancer center, resulting disruptive shifts in utilization
prompted an evaluation of the scheduling processes supporting
the clinical and product pathway from apheresis through pro-
cessing and issuing of products for infusion. Several opportuni-
ties for improvement in staffing, resource scheduling process,
communication, and distribution of work process across time
periods were identified. An analysis of historical volume of
S360 Poster Session IIprocedures, incidences of underutilization and over-allocation
from a scheduling perspective, along with review of overtime
employment of staff, generated further root cause assessment
of several concerning patterns of poor utilization along with
poorly managed spikes in volume which can generate patient
safety risk and employee burn-out. Based on the analysis, a cen-
tralized scheduling process for apheresis was developed and im-
plemented using the existing GE/IDX platform. New guidelines
for apheresis scheduling based on clinical criteria as well as new
rules for scheduling were activated. Restructuring of cell pro-
cessing technical staff work schedules and procedure scheduling
were implemented based on a new assessment of demand and
greater management of procedure scheduling during each pro-
cessing day. Outcomes include significantly greater actual
throughput, improved efficiency of the scheduling process itself,
nearly eliminated overtime, higher staff satisfaction among cell
processing technicians, and reduction of risk-generating volume
spikes.577
OUTPATIENT PHARMACY ESTIMATE OF CHARGE FINANCIAL COUNSEL-
LING
Cruz, E.D., Bramwell, D.P., Shaw, S., Ifokwe, M., Lang, M.,
Lewis, M.S. UT MD Anderson Cancer Center, Houston, TX
Planning for the stem cell transplant (SCT) patient’s discharge is
complex requiring a multidisciplinary team (MDT) approach. Chal-
lenges identified by the MDT include costly prescription co-pays
and limited pharmacy coverage which is overwhelming and frustrat-
ing to patient and MDT.
This challenge led to the creation of a MDT task force. Based on
several meeting discussions and MDT feedback, an outpatient phar-
macy estimate of charge (EOC) process was developed and an EOC
form was designed to address pharmacy co-pays/deductible, high-
dollar prescriptions, annual lifetime maximum and potential dis-
charge medication list, with a goal to counsel all patients prior to
SCT admission.
In October 2009, the Related Coordinator started the new pro-
cess by scheduling the patient’s pharmacy EOC counseling at the
time of pre-admission work-up. The Patient Access Specialist
(PAS) verifies prescription benefits from the health insurance
and reviews coverage with the patient, who signs the EOC form
after counseling. The Patient Access Coordinator addresses ques-
tions related to the medications. The PAS faxes the signed EOC
to the case manager who reviews the EOC with the patient when
planning for discharge. Patients are counseled at the bedside
when appointment is missed. Texas residents who are unable to
financially meet the co-pays/deductible or have limited benefits
are provided with a Supplemental Financial Assistance applica-
tion. The Pharmacy Reimbursement Specialist counsels all Medi-
care, Indigent and Self-pay patients for Pharmacy Assistance
Program.
As a result, patient’s verbalized marked decrease in their anxiety
and increased knowledge on their benefits empowering them to
make informed decisions regarding their discharge prescriptions.
Identification of limited pharmacy coverage prior to SCT admission
enables the MDT timely intervention to address the patient’s di-
lemma. Pharmacy counseling coupled with the EOC form as
a tool enhanced the quality of patient care, increased patient satisfac-
tion and MDT greater job fulfillment.TRANSPLANT NURSING-RESEARCH
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A RANDOMIZED PILOT STUDY COMPARING INFECTION RATES IN MYE-
LOABLATIVE ALLOGENEIC STEM CELL TRANSPLANT PATIENTS RECEIV-
ING A NON-NEUTROPENIC DIET OR A NEUTROPENIC DIET
Lassiter, M., Adler, A. Duke University Health System, Durham, NC
Purpose: The primary objective of this study is to compare the in-
cidence of grade 3 or 4 bacteremia as defined by the NCI CommonTerminology Criteria for Adverse Events (CTCAE) v4.0.in patients
undergoing myeloablative allogeneic stem cell transplant when re-
ceiving a neutropenic diet or a non-neutropenic diet. Secondary ob-
jective is to assess the nutritional status of patients undergoing
myeloablative allogeneic stem cell transplant in those receiving
a neutropenic diet as compared to those receiving a non-neutropenic
diet using the Scored Patient-Generated Subjective Global Assess-
ment (PG-SGA).
Materials andMethods:To date, a convenience sample of 18 mye-
loablative allogeneic hemotopoietic stem cell transplant patients
have been randomized to receive either a neutropenic or non-
neutropenic diet during their period of neutropenia. Several nutri-
tional standard indicators, CBC, and PG-SGAwere assessed weekly.
Blood cultures were obtained per unit standard.
Results: When comparing maximum change in prealbumin, trans-
ferrin, and days of TPN, only borderline statistical difference is de-
tected. Wilcoxon Rank-sums p 5 0.056. The median number of
TPN days for the controls is 18 and for the experimental group
it’s 13, Wilcoxon Rank-sums p5 0.5; therefore, it is not statistically
different. 25% of the controls have a grade 3 blood stream infection
compared to 40% of the experimental, the chi-square test for com-
paring these proportions is 0.50; therefore, these proportions are
not statistically significantly different. No grade 4 blood stream
infections were noted during neutropenia.
Conclusions: This small sample set does not show any significant
difference in grade 3 or 4 infections between the arms of the study.
Days of TPN and overall nutritional status does not appear to be sig-
nificant as well.
Limitations: Small sample size, inconsistent patient recording of
food diaries.
Future directions: Continue enrollment in this study to increase
statistical power of results.579
PALONOSETRON VERSUS ONDANSETRON IN CHEMOTHERAPY INDUCED
NAUSEA AND VOMITTING
Vieira, S., Monroe, D. Trustees of London Clinic, London, United
Kingdom
Introduction: Palonosetron is a longer acting -5 hydroxytrypta-
mine-3 (5-HT3) antagonist, used in preventing chemotherapy in-
duced nausea and vomiting (CINV). It is licensed initially for the
oncology patient group. It is given as an injection and acts over
a five days period.
Method: In our haematology setting we have conducted a small
comparison study to compare the efficiency of Palonosetron and
Ondansetron for haematology patients for preventing CINV. Stage
1 data was collected prospectively for Palonosetron over a year pe-
riod. Second stage data was collected for efficiency of Ondansetron
retrospectively, simply because Ondansetron is the main anti-
sickness drug used in our centre. Patients who were in the Ondan-
setron group were selected randomly without any information
given to ward nurses. The information was collected day 1- day
11 from the day chemotherapy started. There were 24 patients in
each group.
The data was compared in three different categories: complaints of
nausea (severity), vomiting (how many episodes over 24 hour) and
the requirement of additional anti-sickness.
The patients in both groups received similar chemotherapy regi-
mens. Patient demographic data and chemotherapy regimen are
shown Table I.
Result: Due to limited word count of this abstract, the outcome is
evaluated on two sections instead of three: severity of nausea and fre-
quency of vomiting.
According to our study, patients who received Palonosetron suf-
fered less from mild nausea. In this group a maximum of seven pa-
tients reported mild nausea where as 12 patients were reported
similar episodes in the Ondansetron group.
However, in the evaluation of vomiting, there was a trend in the
Palonosetron group. Those patients receiving Palonosetron had
their sickness/ vomiting peak on day 4. Palonosetron was given day
5, where the vomiting subsidised again. However 46% of patients
